The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects elderly persons, evolving with age to reach severe cognitive impairment. Amyloid deposits and neurofibrillary tangles constitute the main pathological hallmarks of AD. Amyloid deposits are initiated by the excessive production and accumulation of beta-amyloid (Aβ) peptides in the brain. The dysfunction of the Neurovascular Unit (NVU) has been proposed to be causative in AD development, due to an impaired clearance of Aβ from the brain. Cells forming the NVU express several Adenosine Triphosphate ATP-Binding Cassette (ABC) transporters, among which ABCB1 and ABCA1 play an important role in Aβ processing. The drug transporter ABCB1 directly transports Aβ from the brain into the blood circulation, whereas the cholesterol transporter ABCA1 neutralizes Aβ aggregation capacity in an Apolipoprotein E (ApoE)-dependent manner, facilitating Aβ subsequent elimination from the brain. In the present minireview, we will summarize the contribution of ABCB1, and ABCA1 at the NVU in Aβ clearance. Moreover, we will outline and discuss the possible collaboration of ABCB1, and ABCA1 at the NVU in mediating an efficient clearance of Aβ from the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 4×
“…cleavage of the Amyloid Precursor Protein (APP) produces beta-amyloid (Aβ) peptides, namely Aβ1−40 and Aβ1−42 (Hardy and Selkoe, 2002), which oligomerize to form small oligomers of 2–12 peptides (i.e., Aβ oligomers), and aggregate leading to Aβ plaques generation (Haass and Selkoe, 2007).”
BackgroundInfluentialAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 13×
“This hypothesis suggests that the dysfunction of the BBB/NVU causatively contributes to the pathogenesis of AD (Zlokovic, 2011), which is now under intense investigation.”
BackgroundMethodInfluentialNeurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
Armulik, A., Genové, G., & Betsholtz, C. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.07.001 · Cited by 2,653 · cited 1×
“Brain pericytes act as vascular smooth cells (vSMC) by expressing several receptors of vasoactive molecules, therefore playing a major role in controlling brain microvascular tone (Armulik et al., 2011).”
BackgroundPericytes are required for blood–brain barrier integrity during embryogenesis
Daneman, R., Zhou, L., Kebede, A. A., & Barres, B. A. (2010) · Nature · doi:10.1038/nature09513 · Cited by 2,128
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050 · cited 1×
“More recently, it has been reported that the stimulation of Retinoid X Receptor (RXR) using the agonist bexarotene in a mouse model of AD enhanced soluble Aβ clearance in an ApoE dependent manner (Cramer et al., 2012).”
Background
Cited by
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Storck, S. E., Hartz, A. M. S., Bernard, J., Wolf, A., Kachlmeier, A., Mahringer, A., Weggen, S., Pahnke, J., & Pietrzik, C. U. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.07.017 · Cited by 143
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
Ultrastructural evidence of microglial heterogeneity in Alzheimer’s disease amyloid pathology
El Hajj, H., Savage, J. C., Bisht, K., Parent, M., Vallières, L., Rivest, S., & Tremblay, M.-È. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1473-9 · Cited by 119
Self-citationABCA7 expression is associated with Alzheimer's disease polymorphism and disease status
Vasquez, J. B., Fardo, D. W., & Estus, S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.09.058 · Cited by 101
“This is suggestive that ABCA7 may act similarly to ABCA1, which has been shown to transfer cholesterol to apoE and modulate amyloid-beta (Aβ) levels [6, 8, 19, 23, 25, 44].”
BackgroundKim, D. K., Park, J., Han, D., Yang, J., Kim, A., Woo, J., Kim, Y., & Mook-Jung, I. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0234-4 · Cited by 95
“In contrast, Abca1, a risk factor for AD, has been reported to play a significant role in Aβ clearance [71].”
BackgroundUllah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
Merino-Zamorano, C., Fernández-de Retana, S., Montañola, A., Batlle, A., Saint-Pol, J., Mysiorek, C., Gosselet, F., Montaner, J., & Hernández-Guillamon, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150976 · Cited by 63
“Other receptors, such as P-glycoprotein (Pgp) and other members of the ATP-binding cassette (ABC) transporter family are also involved in the transport of Aβ across the BBB [12, 13].”
BackgroundHohman, T. J., Bush, W. S., Jiang, L., Brown-Gentry, K. D., Torstenson, E. S., Dudek, S. M., Mukherjee, S., Naj, A., Kunkle, B. W., Ritchie, M. D., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.031 · Cited by 52
Zhang, J., Feng, X., Wu, J., Xu, H., Li, G., Zhu, D., Yue, Q., Liu, H., Zhang, Y., Sun, D., et al. (2014) · BioFactors · doi:10.1002/biof.1149 · Cited by 50
Role of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimer’s Disease
Nanjundaiah, S., Chidambaram, H., Chandrashekar, M., & Chinnathambi, S. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00883-6 · Cited by 36
GJ-4 alleviates Aβ25-35-induced memory dysfunction in mice through protecting the neurovascular unit
Zhang, Z., Liu, H., Zhao, Z., Zang, C., Ju, C., Li, F., Wang, L., Yang, H., Bao, X., Yu, Y., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110131 · Cited by 19
Blood amyloid-β protein isoforms are affected by HIV-1 in a subtype-dependent pattern
The HIV Neurobehavioral Research Center (HNRC) Group, de Almeida, S. M., Ribeiro, C. E., Rotta, I., Letendre, S., Potter, M., Tang, B., Batistela, M., Vaida, F., & Ellis, R. J. (2020) · Journal of NeuroVirology · doi:10.1007/s13365-019-00783-6 · Cited by 14
Transcriptomic predictors of rapid progression from mild cognitive impairment to Alzheimer's disease
Huang, Y.-L., Tsai, T.-H., Shen, Z.-Q., Chan, Y.-H., Tu, C.-W., Tung, C.-Y., Wang, P.-N., & Tsai, T.-F. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01651-0 · Cited by 13
Uvarajan, D., Gnanarajan, R., Karuppusamy, P. A., Ravichandran, N., Govindasamy, C., Vellingiri, B., Narayanaswamy, A., & Wang, W. (2026) · Molecular Biotechnology · doi:10.1007/s12033-025-01392-x · Cited by 7
Metadata
- Authors
- ElAli, A., & Rivest, S.
- Venue
- Frontiers in Physiology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 45-45
- ISSN
- 1664-042X (ISSN-L)
- OpenAlex
- W2110797945
- Cited by
- 108
- References
- 26
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.